Skip to content
★ Sign in to follow
JH

James H. Welch

CFO
Eiger BioPharmaceuticals, Inc.Talphera, Inc.
Total declarations
5
Companies
2
▲ Purchases (5 ops.)
€68k
▼ Sales (0 ops.)
—

Latest filing published 22 Jun 2016 for Eiger BioPharmaceuticals, Inc., €35k.

Insider track record

Disclosed buys
5
Disclosed sells
0
Signal history

Closed purchases

Market purchases
5
Positive at T+90
0%
Median T+90
-16.0%

Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 07 Sept 2011 · 5542 days ago · €17k
    -1.5%
    Entry US$65.20 · Close at T+365 US$64.20

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

James H. Welch: trading record in brief

Filings by James H. Welch span 2 companies, the busiest being Talphera, Inc. and Eiger BioPharmaceuticals, Inc. We count 5 filings; the first trade dates from 6 September 2011 and the latest from 22 June 2016.

No open-market sale appears; the market trades are 5 purchases worth €68k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2016 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €8,735. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -16.0%. Past outcomes like these are no guarantee of what comes next.

On 22 June 2016 came the latest disclosure, an open-market purchase for €35k in Eiger BioPharmaceuticals, Inc. The median gap between trade and publication is zero days: most filings appear on the same day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to James H. Welch

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations5 total
  • ▲
    Chief Financial OfficerExecutivesEiger BioPharmaceuticals, Inc.
    39,600 USD39SEC
    2,000 shares@ US$19.8080.0% of flowCommon StockSEC:0001209191-16-129187:0
    Canonical exit: 18 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesEiger BioPharmaceuticals, Inc.
    9,895 USD35SEC
    500 shares@ US$19.7920.0% of flowCommon StockSEC:0001209191-16-129187:1
    Canonical exit: 20 Sept 2016 (T+90)
  • ▲
    Chief Financial OfficerExecutivesTalphera, Inc.
    23,240 USD0SEC
    7,000 shares@ US$3.32Common StockSEC:0001181431-11-048484:0
    Canonical exit: 5 Dec 2011 (T+90)
  • ▲
    Chief Financial OfficerExecutivesTalphera, Inc.
    6,780 USD0SEC
    2,000 shares@ US$3.39Common StockSEC:0001181431-11-048484:1
    Canonical exit: 6 Dec 2011 (T+90)
  • ▲
    Chief Financial OfficerExecutivesTalphera, Inc.
    3,390 USD0SEC
    1,000 shares@ US$3.39Common StockSEC:0001181431-11-048484:2
    Canonical exit: 6 Dec 2011 (T+90)

5 of 5 declarations